 | | Vol. 12.41 – 22 October, 2020 |
| |
|
|
| The authors describe a method to study whole-tissue extracellular matrix (ECM) effects from disease states associated with metastasis on tumor cell phenotypes and identified the individual ECM proteins and signaling pathways that were driving these effects. They showed that decellularized ECM from tumor-bearing and obese mammary glands drives TNBC cell invasion.
[Science Advances] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators found that active targeting nanoparticles displayed a superior DNA damage capability via enhanced-interactions with DNA and a significantly stronger effect in reducing cancer stem cell-like property of TNBC cells, compared to conventional cisplatin and miriplatin.
[Journal of Controlled Release] |
|
|
|
| Scientists found in breast tumors that the expression of SMAR1 was decreased in cancer stem cells through the cooperative interaction of the pluripotency factors Oct4 and Sox2 with the histone deacetylase HDAC1.
[Science SIgnaling] |
|
|
|
| Single-cell RNA-seq performed on two different TNBC cell samples, infected or not with vaccinia virus, highlighted three distinct populations: naïve cells, bystander cells, defined as cells exposed to the virus but not infected and infected cells.
[PLoS Pathogens] |
|
|
|
| Researchers utilized human tumor samples, cell culture models, and a mammary carcinoma mouse model with tissue-specific Rnf40 deletion and identified an unexpected tumor-supportive role of RNF40 in HER2-positive breast cancer subtype.
[Cell Death & Disease] |
|
|
|
| The authors explored that the expression of TIMELESS circadian regulator (TIM) was elevated in breast cancer, and high expression of TIM in cancer tissues was associated with poor prognosis, especially in the ER-positive breast cancer patient.
[Cell Death & Disease] |
|
|
|
| Scientists crossed the MMTV‐PyMT model of mammary gland tumorigenesis with a TgfbiΔ/Δ mouse and studied the cancer stem cell content of the tumors. They performed RNAseq on WT and KO tumors and analyzed the tumor vasculature and the immune compartment by IHC and FACS.
[Molecular Oncology] |
|
|
|
| Researchers performed Affymetrix Gene Chip miRNA 4.0 microarray and observed differential regulation of miRNAs (75 upregulated and 199 downregulated) in metastatic MDA-MB-231 cells as compared to immortalized human non-tumorigenic breast epithelial cells.
[Scientific Reports] |
|
|
|
| Scientists formulated docetaxel and thymoquinone in borage oil-based nanoemulsion and evaluated its potential in impeding the growth of breast cancer cells.
[Scientific Reports] |
|
|
|
| Investigators elucidated the potential role of a novel lncRNA FGF14-AS2 and the mechanisms underlying metastasis in breast cancer.
[Cell Death Discovery] |
|
|
|
| Scientists demonstrated that the expression of FOXC1 was associated with resistance of doxorubicin treatment of breast cancer cells.
[Acta Pharmacologica Sinica] |
|
|
|
| Researchers performed precise 2D mechanical phenotyping based on power-law rheology to unveil the contributions of myosin II, actin fiber architecture, and energy metabolism to the deformability of healthy (MCF-10A), noninvasive cancerous (MCF-7), and metastatic (MDA-MB-231) human breast epithelial cells.
[Communications Biology] |
|
|
|
|
| Investigators provide an overview of the latest research in the single-cell genomics of mammary gland development, which may help to understand the lineage commitment of mammary stem cells into luminal or basal epithelial cells that constitute the mammary gland.
[Seminars in Cell & Developmental Biology] |
|
|
|
| To determine if gene expression analysis has been a successful approach for variant classification, the authors describe the design and comparability of 23 published gene expression studies that have profiled cells from BRCA1– and BRCA2 pathogenic variant carriers.
[Cancers] |
|
|
|
|
| Agendia, Inc. announced that the Federal Joint Committee approved MammaPrint®, Agendia’s 70-Gene Breast Cancer Recurrence Assay.
[Agendia, Inc.] |
|
|
|
|
| January 25 – January 28, 2021
Virtual |
|
|
|
|
|
| | University of Oslo – Oslo, Norway |
|
|
|
| | Institute of Cancer Research – London, England, United Kingdom |
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | Institute of Cancer Research – London, England, United Kingdom |
|
|
|
| | Dalhousie University- Halifax, Nova Scotia, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
